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Background: The benefits of the long-term administration of oral anticoagulant therapy remain unclear in patients with 
lower extremity arterial bypass surgery. We studied the effect of warfarin plus aspirin therapy (WASA) versus aspirin 
therapy alone (ASA) on patient mortality, morbidity and bypass patency rates in a randomized clinical trial. 
Methods: In a multicenter, prospective, nonmasked clinical trial, 831 patients who underwent peripheral arterial bypass 
surgery were compared in a long-term treatment program of WASA (target international normalized ratio of 1.4 to 
2.8; 325 rag/day) with ASA (325 rag/day). The primary end point was bypass patency, and mortality and morbidity 
were the secondary endpoints. 
Results: There were 133 deaths in the WASA group (31.8%) and 95 deaths in the ASA group (23.0%; risk ratio, 1.41; 
95% confidence interval, 1.09 to 1.84; P = .0001). Major hemorrhagic events occurred more frequently in the WASA 
group (WASA, n = 35; ASA, n = 15; P = .02). In the prosthetic bypass group, there was no significant difference in 
patency rate in the 8-mm bypass subgroup, but there was a significant difference in patency rate in the 6-mm bypass 
subgroup (femoral-popliteal; 71.4% in the WASA group versus 57.9% in the ASA group; P = .02). In the vein bypass 
group, patency rate was unaffected (75.3% in the WASA group versus 74.9% in the ASA group). 
Conclusion: The long-term administration of warfarin therapy when combined with aspirin therapy has only a few 
selected indications for improvement of bypass patency and is associated with an increased risk of morbidity and mor- 
tality. (J Vasc Surg 2002;35:413-21.) 
Each year approximately 100,000 arterial bypass proce- 
dures are perfbrmed in the United States for the improve- 
ment of  lower extremity circulation. 1 Current practice 
suggests that the patency of  an arterial bypass to the lower 
extremity is benefited by the long-term administration of  
aspirin therapy. 2 After 5 years, 45% to 60% of prosthetic 
bypasses and 60% to 75% of vein 3 bypasses remain patent 
and 40% to 50% of the patients may have died.4, 5The lead- 
ing cause of death is usually a cardiac disorder. Flinn et al6 
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have reported that the chronic administration of  warfarin 
therapy may improve prosthetic bypass patency in selected 
patients. Several European studies have reported that war- 
latin therapy is also beneficial in patients with lower extrem- 
ity vein bypasses. 7-9 However, it remains controversial 
whether warfarin has an acceptable risk/benefit outcome 
for patients who undergo lower extremity revascularization. 
Several studies 10q4 in patients with cardiac disorders or 
deep vein thrombosis have indicated that the chronic 
administration of  warfarin therapy at a low dosage is as 
effective and safer than the higher dosage regimes, and this 
has prompted interest in the clinical use ofwarfhrin therapy 
for the improvement of  lower extremity bypass patency. 
Combined treatment, in which platelet function and fibrin 
tbrmation are simultaneously modified, may be more effec- 
tive in the prevention of  bypass thrombosis than either 
agent alone. We hypothesized separately for prosthetic and 
vein bypasses that a program of low dosage oral anticoagu- 
lation therapy plus aspirin would improve the patency per- 
fbrmance of vascular bypasses and as a secondary benefit 
would also reduce the incidence of occlusions in the coro- 
nary and cerebral circulation. To test these two hypotheses, 
Veterans Affairs (VA) Cooperative Study #362 was initiated. 
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Fig 1. Schematic presentation f study participants with loss of 
bypass patency. ASA~ Aspirin therapy. 
METHODS 
Design. The protocol for this randomized, non- 
masked study was approved by the Cooperative Studies 
Evaluation Committee, the Human Rights Committee of 
the Cooperative Studies Program Coordinating Ccntcr 
(CSPCC), Dcpartment of VA, Perry Point, Md, and by the 
institutional review board at each of the 17 participating 
centers. All the paticnts gave written intbrmcd conscnt. 
Eligibility. From October 1, 1991, to Scptembcr 30, 
1995, all patients scheduled for elective axillofemoral, 
tkmoral-tkmoral, femoral-popliteal, or fEmoral-distal bypass 
surgery at 17 Department of VA Medical Centers under- 
went evaluation tbr participation i a prospective random- 
izcd study of the cfficacy of the addition of oral 
anticoagulation therapy to the long-term administration f
aspirin therapy. At each t~tcility, a participating vascular sur- 
geon and a study coordinator (Appendix, online only) were 
responsible for patient cnrolhnent and serial follow-up 
cxamination. The patients undcrwent evaluation with a 
standardizcd history that categorized arterial ischemic 
symptoms to disabling claudication, rest pain, or tissue loss. 
Thc risk i5ctors that were prospectively recorded included 
the prcsence of diabetes, prior vascular econstruction, 
hcart discase, ccrebral vascular events, or smoking. Paticnts 
with calcified vessels, ankle brachial index (ABI) of more 
than 0.9 in the recipient limb, prior prosthetic bypass in the 
samc location, known hypercoaguablc state, or contraindi- 
cations to aspirin or warfarin therapy (such as peptic ulcer 
disease or esophageal varices, history of gastrointestinal, 
genital-urinary, retinal, or intracranial bleeding, and penile 
injections for impotency) were excluded from study partic- 
ipation. Other exclusionary factors were: emergency 
surgery, short (<1 year) life expectancy, serum crcatinine 
value more than 2.5 or bilirubin value more than 1.5 
mg/dL ,  polycythemia (red blood cell count, >7.5 x 
106/ram3), or platelet count more than 106/mm 3. In 
patients with infrainguinal revascularization, a patient with 
a fhilcd ipsilateral vein bypass could not undergo a second 
vein bypass procedure but could receive aprosthetic bypass. 
Likewise, a patient with a failed prosthetic bypass could not 
undergo another prosthetic bypass procedure but could 
receive a vein bypass. No anastomotic vein cuffs were used 
with prosthetic bypasses. All patients were to undergo ther- 
apy with 325 mg of aspirin the day before surgery. Heparin 
administration was not regulated but was routinely admin- 
istered uring surgery and rarely after surgery. 
Stratif ication and randomization. On the 1st post- 
operative day, patients with patent bypasses were initially 
stratified by center and by bypass material (prosthetic 
bypass or autogenous vein bypass). There was a secondary 
stratification process for 8-mm and 6-ram diameter pros- 
thetic bypasses. After stratification, patient randomization 
was accomplished with a telephone call to the Perry Point, 
Md, Cooperative Studies Program Coordinating Center 
for warfarin plus aspirin therapy (WASA) or aspirin therapy 
alone (ASA). Warfarin therapy (usually 5 mg/day) was ini- 
tiated as soon as the patient's condition tolerated oral flu- 
ids. The "low dose" target international normalized ratio 
(INR) was 1.4 to 2.8, a dose requested by the Food and 
Drug Administration. Warfarin was donated by Dupont 
Pharma (Wilmington, Del). Enteric coated aspirin was 
administrated at 325 mg/day. 
Postoperative pat ient fol low-up bypass surveil- 
lance. The patients with warfarin therapy had monthly 
monitoring of the INR and warfarin dose adjustment to 
meet the target INR. Warfarin therapy was withdrawn if a 
major hemorrhagic event occurred (intracranial b eed, hos- 
pitalization for bleeding, an operation for control of bleed 
ing, or a blood transfusion), if the patient's primary 
physician believed that thrther warfarin therapy was unsafe, 
or if the patient requested to have the therapy withdrawn. 
Follow-up examination of such patients continued. 
All the patients undcrwent evaluation every 3 months 
for the current status of their lower extremity arterial cir- 
culation with symptomatic complaints, palpation of arte- 
rial pulses, and ABI. Bypasses were considered patent if 
the postoperative ABI remained at 0.15 or more above the 
preoperative value, a slightly higher level than originally 
proposed (>.10) by the Ad Hoc Committee fbr Vascular 
Surgery. Is Whenever the patency of a bypass was in doubt, 
a duplex scan ultrasonic evaluation or an angiographic 
study was performed. Patency rates reported in this study 
are "assisted primary" patency rates, 16 because bypass revi- 
sion was permitted for bypasses identified as patent but 
stenotic. Patients were terminated from the study and cen- 
sored in the statistical analyses at the time of death, an 
above-knee or below-knee amputation, or additional 
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Table I. Baseline characteristics of 831 patients according to study arm and treatment group 
Characteristic 
Prosthetic bypass (n = 373) Vein bypass Oz = 458) 
WASA (n ~ 187) ASA (n = 186) WASA (n = 231) ASA (n = 227) 
Age (y) 63.4 _+ 8.7 62.7 +_ 8.0 65.6 +_ 7.6 64.8 _+ 7.9 
White race 74.3% 82.3% 74.7% 72.7% 
Prior myocardial inthrction 30.0% 27.4% 18.6% 23.5% 
Current treatment for hypertension 87.2% 84.8% 90.6% 89.0% 
History of diabetes 3 ] .0% 29.6% 51.5% 51.8% 
Prior stroke 16.6% 17.2% 17.8% 17.6% 
Cholesterol level (mg/dL) 200.9 ± 47.6 203.0 _+ 49.2 187.2 _+ 48.3 192.1 _+ 52.8 
Hematocrit 41.8% -+ 4.9% 41.5% _+ 5.7% 39.7% _+ 5.2% 39.7% _+ 5.0% 
Ankle brachial index 0.40 _+ 0.17 0.40 +_ 0.18 0.37 _+ 0.17 0.40 -+ 0.18 
Previous vascular operation (cardiac, carotid, ext emity)* 51.9% 59.5% 54.0% 41.2% 
*P < .01 in vein stud?/" arm. 
WASA, Warfarin and aspirin therapy; ASA, aspirin only therapy. 
inflow or outflow bypass in the study leg or if the patient 
could not be located for at least 12 months. All other 
patients were fbllowed until September 1997. 
Statistical analysis. All the analyses performed 
included all 831 randomized patients on an intent-to-treat 
basis with two-sided P values. The patients were not cen- 
sored or withdrawn from observation if their randomized 
treatment program was changed. The primary outcome 
was assisted primary patency; mortality was a secondary 
outcome, Each of the two stratified prosthetic and vein 
study groups were individually powered fbr detection of 
an improvement in patency rate of at least 15%, with a type 
I error rate of 5% and power f}om 80% to 90% if between 
374 and 500 patients were randomized in the prosthetic 
group (with an estimated ASA control group patency rate 
of 55%) or if between 350 and 468 patients were random- 
ized into the vein group (with an estimatcd ASA control 
group patency rate of 60%). A 15% or less patient loss or 
dropout rate was included in these calculations. 
A stratified log-rank statistic was used for comparison 
of the patency and survival rate distributions in the two 
study treatment groups. Kaplan-Meier method was used 
in the construction of life-table plots. In comparison of 
the two treatment groups, risk ratios associated with the 
event were estimated and 95% confidence intervals were 
calculated f?om the Cox proportional hazards model. The 
Cox proportional hazards model was also used in testing 
fbr interactions between treatment groups and predefined 
variables that included age, prior myocardial infarction, 
and history of hypertension, diabetes, stroke, or prior 
bypass. All analyses were performed with a backward 
(covariate) elimination procedure with the six covariates. 
A Data and SafEty Monitoring Board (Appendix, 
online only) reviewed the data annually. September 30, 
1997, was the prechosen date on which patient follow-up 
examination would be terminated. 
RESULTS 
A total of 2586 patients cheduled for lower extremity 
revascularization were screened, of whom 882 (34%) met 
the criteria for entry into the study before surgery. Of 
these patients, 51 subsequently became ineligible, and 831 
(32%) were enrolled beginning on October 1, 1991. 
Enrollment was completed for patients for vein bypass on 
September 30, ] 995, and for patients for prosthetic bypass 
on September 30, 1996 (Fig 1), Follow-up examination 
was completed by September 30, 1997. Three hundred 
seventy-three patients with prosthetic bypasses and 458 
patients with vein bypasses were randomized to WASA or 
ASA. This represented 99.7% of the patients needed tbr 
80% power in the prosthetic group and 97.9% of the 
patients needed for 90% power in the vein group. The 
patients were all male except for six females: one in the pros- 
thetic group and five in the vein group. No randomized 
patient was excluded from analysis. 
The two treatment programs were similar in their 
baseline characteristics, as can be seen in Table I. There 
were variables within the bypass groups that were not 
evenly distributed: a mean serum cholesterol level of 202 
mg in the prosthetic group and of 189 mg in the vein 
group, prior myocardial infarction of 29% in the prosthetic 
group and of 21% in the vein group, and history of dia- 
betes of 31% in the prosthetic group and of 52% in the 
vein group. Within the vein group, there was a significant 
difference in the proportion of patients who had had pre- 
vious bypass operations (54% in the WASA treatment pro- 
gram and 41.2% in the ASA treatment program; P < .01). 
In the vein group, the operative technique was in situ in 
220 patients (111 WASA and 109 ASA), reversed saphe- 
nous vein in 193 patients (98 WASA and 95 ASA), and 
transposed, composite, etc, in 34 patients (16 WASA and 
18 ASA). 
Prosthetic bypass patency. For patients with pros- 
thetic bypasses, there were 44 patients (23.5%) with 
bypass occlusion in the WASA group and 64 (34.4%) in 
the ASA group (risk ratio, 0.62; 95% confidence intcrval, 
0.42 to 1.92; P = .017). The average follow-up period was 
36.6 months. The cumulative assisted primary patency 
rate for a prosthetic bypass is presented in Fig 2,A. In the 
161 patients with 8-ram bypasses (axillofemoral, femoral- 
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femoral, and a few femorabpoplitcal abovc-knec bypasses), 
there was no significant dift~rencc in tack of patency (17% 
in the WASA group versus 24.1% in the ASA group; P = 
.32). However, in the 212 paticnts with 6-ram bypasses, 
there was a significant difference in the lack of patency 
(28.6% in the WASA group versus 42.1% in the ASA 
group; P = .022). Cumulative assistcd primary patcncy 
rate in different bypass locations is prcsented in Table II. 
For patients with t~moral-popliteal bypasses in the above- 
knee position, treatment with WASA providcd a signifi- 
cantly improvcd patency rate. 
Eighty-six patients were censored with patent bypasses: 
14 were lost to follow-up examination ( ine WASA and five 
ASA), nine (thrce WASA and six ASA) had a major ampu- 
tation with a patcnt bypass, three aspirin treatmcnt had a 
new bypass involving the study limb, and 62 died (40 
WASA and 22 ASA). At the timc of prosthetic bypass 
thrombosis in the WASA group, 14 patients had an INR 
betwcen 1.4 and 2.8, two had an INR of more than 2.8, 
nine had an INR of less than 1.4, five had not had an INR 
detcrmination during the prior 30 days, 13 patients were no 
longer undergoing WASA, and one patient had an early 
postoperative bypass thrombosis befbre an INR was deter- 
mined. During follow-up evaluation, 69 of the patients 
(37%) had warfarin therapy permanently discontinued while 
their bypass was patent; 26 of these 69 also had aspirin ther- 
apy discontinued. Of the 4077 postoperative INR determi- 
nations, the frequency of a low INR value in patients with 
fhiled bypasses (35.4%) was significantly (P = .04) higher 
than in patients with patent bypasses (30.4%). 
Vein bypass patency. There were 57 patients (25.1%) 
in whom patency was lost in the ASA group and 57 
(24.7%) in whom patency was lost in the WASA group 
(risk ratio, 1.04; 95% confidence interval, 0.72 to 1.51; P 
= not significant). Thc average tbllow-up period was 39.3 
months. The cumulative assisted primary patency rate was 
not significantly different between the two groups (Fig 
2,B). Subset analysis for femoral-popliteal bove-knee, 
femoral-poplitcal below-knee, or femoral-tibial/peroneal 
bypasses did not show any significant benefit for warfhrin 
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Table II. Bypass type with cumulative patency rates 
Bypass ~. pe No. of bypasscs 1 year 
Cumulative assisted primm 7 pate~lcy rate 
2 year 3 year 4 year 5 year P value 
Prosthetic bypass 
Fcmoral-popliteal above-knee 
Aspirin 103 79% 
Aspirin/warfarin 104 88 % 
Femoral-femoral 
Aspirin 47 87% 
Aspirin/warfarin 48 93% 
Axillo femoral/fe moral 
Aspirin 21 81% 
Aspirin/warfarin 19 84% 
Vein bypass 
Femoral popliteal above-knee 
Aspirin 24 96% 
Aspirin/warfarin 29 86% 
Fcmorabpopliteal below-knee 
Aspirin 60 88% 
Aspirin/warfhrin 56 83% 
Femoral-tibial/pcroneal 
Aspirin 119 87% 
Aspirin/war thrin 119 85 % 
Femoral-pedal 
Aspirin 21 65% 
Aspirin/warfarin 25 92% 
74% 66% 58% 47% 
81% 77% 70% 70% .012 
79% 79% 79% 79% 
91% 86% 72% 72% .79 
76% 66% 44% 44% 
77% 77% 77% 77% .81 
96% 96% 96% 96% 
86% 81% 81% 81% .198 
77% 74% 74% 51% 
79% 76% 56% 56% .843 
84% 82% 74% 71% 
78% 78% 69% 60% .346 
60% 54% 45% 45% 
83% 71% 7]% 71% .089 
therapy. In the 46 patients with pedal bypasses, there was 
a trend (P = .089) in favor of the WASA group (Table II). 
One hundred forty-rive patients were censored with a 
patent bypass: 14 were lost to follow-up (four WASA and 
10 ASA), four had a new bypass involving the study limb 
(one WASA and three ASA), 22 (14 WASA and eight 
ASA) had a major amputation with a patent bypass, and 
105 died (59 WASA and 46 ASA). At the time of vein 
bypass thrombosis, 14 patients had an INR between 1.4 
and 2.8, one had an INRofmore than 2.8, 11 had an 1NR 
of less than 1.4, three had not had an INR determination 
during the prior 30 days, 23 were no longer undergoing 
warfarin treatment, and five had an early postoperative 
thrombosis before an INR was determined. During fol- 
low-up evaluation, 97 patients (42%) had warfarin therapy 
permanently discontinued while their bypass was patent; 
30 of these 97 also had aspirin therapy discontinued. Of 
the 4860 postoperative INR determinations, there was no 
difference in the frequency of a low INR between patients 
with failed or patent bypasses. 
In December 1996, the Data Monitoring Board noted 
that patients with vcin bypasses had no benefit from war- 
farin therapy in terms of patcncy but a probable increase 
in morbidity rate. It was thercfore recommended that the 
continued administration of warfarin bc reevaluated in
each participating patient knowing that thc risks probably 
outweighed the benefits. This lcd to thc subsequent with- 
drawal of warfarin therapy in most patients with a vein 
bypass in the WASA group. 
Mortal ity and morbidity. Therc were 133 deaths 
(31.8%) in the WASA combined (prosthetic and vein) 
group as compared with 95 deaths (23.0%) in the ASA 
combined group (risk ratio, 1.41; 95% confidence interval, 
1.09 to 1.84; P = .01). Besides the covariate analysis, the 
combined mortality analysis included an adjustment tbr 
bypass group (prosthetic or vein). The causes of death for 
each arm are listed in Table III. The cumulative survival 
rate curves for the prosthetic and vein groups, respectively, 
are shown in Figs 3,A and 3,B. The ASA combined (pros- 
thetic and vein) treatment group had a significantly higher 
survival rate as compared with the WASA group (P = 
.010). However, although this difference favoring the 
ASA treatment group remained significant (P = .037) in 
the vein patient group, it was nonsignificant (P = .087) in 
the prosthetic group. The increased frequency of cancer 
deaths appears to be a major factor tbr the increased mor- 
tality rate in the WASA group. Warfarin did not provide 
additional protection as compared with aspirin alone for 
the risk of cerebral events, myocardial infarction, throm- 
boembolic events, or need for hospitalization (Table III). 
Hemorrhagic events. The hemorrhagic events that 
occurred uring the study period are presented in Table 
IV. During the 848 patient years of warfarin therapy, 
there were six hemorrhagic deaths (0.007/treatment 
year). Four patients ustained lethal intracranial hemor- 
rhage. One case occurred after 18 months of treatment 
with an INR of 3.5 during treatment with alternating 
daily doses of 5/7.5 mg of warfarin. The second case had 
a transient ischemic attack (associated with a vertebral 
artery occlusion) when warfarin therapy was being 
reduced in preparation for a contralatcral leg bypass. The 
warfarin therapy was restarted at 7.5 mg/day, and then 4 
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Fig 3. Patient survival rates with prosthetic (A) and vein bypasses (B). 
weeks later, the patient had a fatal intracranial bleed at 
another facility (no INR or computed tomographic scan 
information is available). The third patient died of an 
intracranial bleed after 14 months of warfarin treatment 
with an INR of 2.4. The fourth patient had a diffuse fatal 
subarachnoid hemorrhage during treatment with heparin 
and urokinase in an attempt to lyse a thrombosed bypass. 
Two patients in the WASA group, from different centers, 
had their saphenous vein bypass rupture and died: one 
on the fourth postoperative day (prothrombin time = 
15.8/12.8) exsanguinated from his groin and the other 
had the mid portion of his in-situ bypass rupture on the 
20th postoperative day ( INR = 1.9), had a cardiac arrest 
with anoxic encephalopathy, and subsequently died 6 
months later. One patient in the ASA group with a vein 
bypass died from a subdural hematoma. 
Thirty-five patients in the WASA group and 15 
patients in the ASA group had major hemorrhagic com- 
plications (P = .02; Table IV). Transfusions were adminis- 
tered more frequently in the WASA group (24 versus 11 
patients). Medical intervention fbr a bleeding problem 
occurred more frequently in the patients treated with war- 
f~arin (62 versus 29). Minor events, such asepistaxis, bruis- 
ing, and minor bleeding, also occurred more fi'equently in
the patients treated with warf;trin (199 versus 112). 
D ISCUSSION 
Patency. The results of this prospective randomized 
study show that the addition of warfarin therapy does not 
provide enhanced patency benefit beyond that provided 
by aspirin for most arterial bypasses to the lower extrem- 
ity. However, the data do suggest that some subgroups of 
patients may benefit from chronic oral anticoagulation 
therapy. We found that warfarin therapy improves the 
patency rate of prosthetic bypasses in the femoral-popliteal 
above-knee position. The addition of warfarin therapy did 
not improve routine vein bypass patency rates. The Dutch 
Oral Anticoagulant or Aspirin study (BOA), 17 which eval- 
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Table I I I .  Clinical events 
Prosthetic bypass Vein bypass 
WASA ASA WASA ASA 
No. of deaths 54 39 79 56 
Causes of death 
Heart 17 19 34 29 
Stroke 5 1 3 4 
Cancer 15 7 18 8 
Lung cancer 5 4 10 5 
Pneumonia/sepsis 8 6 9 9 
Intracranial hemorrhage 3 0 1 1 
Unknown 2 3 6 3 
Other* 4 3 7 3 
MI 13 29 24 
Cerebral events 
Stroke (nonlethal) 9 8 14 16 
TIA/RIND 5 8 9 6 
DVT/PE 2 2 3 1 
Hospitalizations 123 125 162 167 
*Other events inprosthetic bypass warfhrin group inclnded puhnonary emboli (n = 2), cirrhosis (n = 1 ),and renal failure (n = 1). Other events in prosthetic 
bypass aspirin group were mesenteric is hemia (n = 2) and suicide (n = i). Other events in vein bypass warfarin group included pulmonary emboli (n = 2), 
auto accident (n = 1), diabetic oma (n = 1), graft rupture (n = 2), and renal failure (n = 1 ).Other events in vein bypass aspirin gronp included mesenteric 
ischemia (n = 1), renal failure (n = 1 ), and supranuclear palsy (n = 1 ). 
WASA, Warfhrin and aspirin therapy; ASA, aspirin only therapy; MI, myocardial infarction; TIA, transient ischemic attack; RIND, reversible ischemic neu 
rologic deficit; DVT, deep vein thrombosis; PE, pulmonary embolism. 
uated the efficacy of  an oral anticoagulant therapy alone 
with a target INR of 3.0 to 4.5 as compared with aspirin 
alone (80 rag) in patients with infrainguinal bypass 
surgery, also tbund a different response in patients with a 
prosthetic bypass as compared with those with a vein 
bypass, Patients with a prosthetic bypass had an improved 
patency rate in the aspirin alone treatment group (risk 
ratio, 1.26). As we compare these two randomized studies 
in patients with a prosthetic bypass, it appears that the 
aspirin treatment may provide the major benefit and oral 
anticoagulation therapy may provide a lesser benefit but 
that when combined their benefits may be additive. This 
speculation is supported by the Antiplatelet Trialists meta- 
analysis that suggests aspirin treatment improves patency 
in patients with arterial peripheral bypass procedures. 2 In 
this VA Cooperative study, the most improvement was 
noted for patients with a 6-mm femoral-popliteal bypass, 
which supports the observations of  Flinn et al,6 who have 
recommended warfarin therapy for patients with inI?ain- 
guinal prosthetic bypasses. 
In patients with a vein bypass, the BOA study noted 
fewer occlusions in the oral anticoagulation therapy group 
(risk ratio, 0.69) 17 as compared with the aspirin group. A 
previous tudy had reported similar findings. 9 How do we 
reconcile the results of the BOA study with those of  this 
VA study that suggest hat warfarin treatment provided no 
additional benefit beyond that already provided by aspirin 
alone? One possibility might be that the target INR (1.4 
to 2.8) was too low in this VA study and that a higher tar- 
get level of 3.0 to 4.5, as used in the BOA study, is needed 
to provide benefit for patients with a vein bypass. Or alter- 
natively, the 100-rag dose of  aspirin as used in the BOA 
study was ineffective as compared with a 325-mg dose in 
our study. Our data are supported by Arfvidsson ct al, 18 
who also found no benefit tbr warfarin therapy. Warfarin 
therapy may bc of  benefit for patients with high-risk 
bypasses fie, poor conduits, poor run-off; or rcdo infrain- 
guinal bypass procedures). Sarac et all9 reported a trial 
restricted to thcsc high-risk conduits with a 3-year assisted 
primary patency rate of  77% in patients with WASA as 
compared with 56% in patients with ASA. VA Cooperative 
Study #362 excluded most of  these patients at high risk, 
but there was a suggestion in our study that patients with 
an initial femoral-pedal bypass, possibly a high-risk group, 
may have received benefit from warfarin therapy (Table 
II). In prospective randomized studies of  coronary artery 
vein bypasses, the Post Coronary Artery Bypass Graft 
Trial 2° failed to show any benefit of  warfarin therapy with 
evaluation with angiography after 6 months of  observa- 
tion, and Gohlke et a121 showed a benefit of  warfarin treat- 
ment over a no-treatment control group. 
A limitation of  our study may be the reduced use of  
warfarin therapy among patients randomized to warfarin 
therapy. Because only about two thirds of  our patients 
remained permanently on warfarin therapy, the potential 
benefit on patency may have been masked. However,  
because in the United States warfarin administration is not 
a routine treatment program for patients with vascular 
bypasses, the patients in this trial were allowed to discon- 
tinue their warfarin therapy at any time after randomiza- 
tion. This freedom to withdraw from warfarin therapy may 
account for the 16% of the study patients who stopped 
taking warfarin for personal reasons. The repeated need 
for venipuncture and the increased frequency of  ecchy- 
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Tab le  IV. Hemorrhagic events 
Prosthetic bypass Vein ~ypass 
WASA ASA WASA ASA 
Major events 
Deaths 
Intracranial bleed 3 
Hemorrhage from bypass rupture 0 
Operation required 
Gastric resection 0 
Lung resection 0 
Nonlcthal hemorrhagic stroke 0 
Transfusion needed 
Gastrointestinal bleeding 3 
Anemia 1 
Epistaxis 0 
Postoperative hematoma 1 
Total major events 8 
Minor events 
Epistaxis 25 
Easy bruising 47 
Prolonged bleeding 28 
Medical intervention needed 24 
0 1 1 
0 2 0 
1 1 0 
0 ] 0 
0 2 1 
1 I4 6 
1 5 3 
0 1 0 
0 0 1 
3 27 12 
11 24 11 
30 52 29 
18 23 13 
8 38 2l 
WASA, Warfarin and aspirin therapy; ASA, aspirin only therapy. 
moses were frequently citcd as a barrier to continued war- 
farin anticoagulation therapy (adverse events warranted 
the withdrawal of warfarin therapy in only 8.8% of" 
patients). The observation that about 40% of our patients 
who were randomized to warfarin therapy were off treat- 
ment at the end of their patency observation is similar to 
other studies that have prospectively evaluated the thera- 
peutic efficacy of warfarin therapy. 22 There is additional 
concern that one third of thc patients may also have had 
an INR less than our minimum target level of 1.4. Other 
investigators have also reported a similar portion of INKs 
were also at less than target. 17 Because this study was not 
blinded, the patients knew they were undergoing warfarin 
therapy. There is a potential bias that thcse patients wcre 
treated differently than those in the ASA group. We 
acknowledge this bias but believe that i  did not affect the 
endpoint analysis, as these were well defined. 
Morta l i ty  and morbidity.  The increase in morbidity 
and mortality rate associated with the chronic administra- 
tion of warfarin to patients with peripheral vascular disease 
was unexpected. The anticipated secondary benefit ofwar- 
fhrin therapy to reduce the risk of mortality from heart dis- 
ease, cerebral vascular disease, or pulmonary emboli did 
not occur, and the increase in hemorrhagic event and can- 
cer mortality rates contributed to an overall survival bene- 
fit for the ASA program (Table III). These observations 
are consistent with the results of the Thrombosis 
Prevention Trial (TPT), 22 a primary prevention study of 
ischcmic heart disease, in which death (2.8%) from heart 
disease and stroke was similar in the WASA group (target 
INR, 1.3 to 1.8) as compared with the ASA group (100 
mg; 3.0%). Likewise, nonfatal myocardial infarction 
occurred at the same frequency (3.7%) in each group, as 
did nonfatal stroke (1.3%). The BOA study did suggest a
mild reduction in vascular death, myocardial infarction, 
stroke, or amputation in the oral anticoagulant group as 
compared with the aspirin group (risk ratio, 0.89). t7 
In our study, most of the increase in mortality rate was 
rclated to an increased canccr mortality rate. There arc 
only a few studies from which to draw comparative data. 
In the TPT, 22 thc WASA group had a total mortality rate 
(8.07%) only slightly lower than tile ASA group (8.9%), 
with no real diffi:rcnce in cancer mortality rate. In thc 
BOA study, 17 death from all causes was slightly higher in 
the oral anticoagulant group (risk ratio, 1.02); cancer 
deaths werc not reported, and follow-up period was 
shorter than in this VA study. Other reports on the rela- 
tionship between warfarin therapy and cancer include 
those of Schuhnan and Lindmarker, 23 who evaluated the 
incidence rate of cancer in patients with deep vein throm- 
bosis who underwent treatment fbr a shorter duration 
(either 6 weeks or 6 months), and of Zacharski et al, 24 
who evaluated the therapeutic value ofwarfhrin therapy in 
treating patients with established ncoplasms. Future stud- 
ies that evaluate the long-term administration of oral anti- 
coagulants hould focus on all causes of death to clarify 
whether the incidence rate of cancer and overall morbidity 
or mortality is affected by the administration of warfhrin. 
Hemorrhagic  events. In this study of elderly veteran 
paticnts with lower extremity bypass urgery, the risk of a 
major bleeding event was 0.041/patient year in a patient 
in the WASA group with a targct INR of 1.4 to 2.8 and 
0.015/pat ient  year in a patient in the ASA group. The 
TPT, 22 with a lower dose of warfarin (INR, 1.3 to 1.8) 
and aspirin (75 mg), had an increased risk of significant 
bleeding (0.0015/pat ient  year) as compared with ASA 
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(0 .0010/pat ient  year). The  h igher  dose o f  ant icoagulants  
and  older pat ient  part ic ipat ion with more  medical  prob-  
lems in this VA s tudy  may have placed our  pat ients at a 
h igher  risk o f  b leeding.  In the BOA study, 17 major  bleed- 
ing  events  occurred twice as of ten in the oral ant icoagu-  
lant  g roup  (0 .047/pat ient  year)  as compared  w i th  the  
aspir in g roup .  In  Turp ie  et al's 25 series o f  pat ients  w i th  
atrial f ibr i l lat ion,  the  target  INR was 3.0 to 4 .5  and  
pat ients  were at an even h igher  risk for major  b leed ing in 
the  WASA group  (0 .085/pat ient  year). 
Th is  s tudy did conf i rm,  as others  have repor ted ,  that  
the  long- te rm admin is t rat ion  o f  warfar in does increase the 
risk o f  lethal intracranial  hemorrhage .  In  the BOA study, 17 
there  were e ight  fatal intracranial  hemorrhages  in 1326 
pat ients  wi th  warfar in therapy as compared  w i th  three in 
the  aspir in g roup  (1324 pat ients)  dur ing  the 21 months  o f  
average fo l low-up per iod.  In  the  TPT ,  22 there were seven 
thtal intracranial  hemorrhages  in the  WASA group  (1277 
pat ients) .  Turp ie  et a125 repor ted  six fatal intracranial  hem-  
o r rhages  in 360  pat ients  w i th  atrial f ibr i l lat ion ( ta rget  
INR,  3.0 to 4.5)  tb l lowed for a mean o f  2.5 years, wh ich  
is about  twice the risk ( four o f  418)  seen in our  pat ients  
w i th  per ipheral  vascular  disease and a lower target  INR.  
Comment .  In  summary ,  for pat ients  w i th  a lower  
ext remi ty  arterial bypass,  chron ic  aspir in admin is t ra t ion  
remains  the mainstay  o f  ant i th rombot ic  therapy to p revent  
bypass  th rombos is  2 and  o ther  card iovascu lar  events .  26 
Low dosage warfar in therapy  may prov ide some addit ional  
patency  benef i t  for pat ients  wi th  a femoral -popl i tea l  pros-  
thet ic  bypass and  for pat ients wi th  a vein bypass that  is at 
h igh  risk fbr th rombos is .  However ,  the  addi t ion  o f  war- 
thrin therapy does signif icantly increase the risk o f  hemor -  
rhagic events.  
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